Timely and individualized heart failure management: need for implementation into the new guidelines

Area of Science:

• Cardiology
• Pharmacology
• Medical Devices

Background:

• Heart failure (HF) management has seen significant progress over 30 years, reducing mortality and hospitalizations in patients with reduced ejection fraction (HFrEF).
• Guideline-directed chronic HF therapy optimization remains crucial for improving outcomes.
• Established device therapies like implantable defibrillators and cardiac resynchronization have enhanced patient prognosis and symptoms.

Purpose of the Study:

• To review novel developments in pharmacological and device therapy for HFrEF.
• To discuss strategies for implementing these new therapies into clinical practice.
• To identify pathways for further improving outcomes in HFrEF patients.

Main Methods:

• Review of recent literature on HFrEF treatments.
• Analysis of new drug classes targeting various pathways (e.g., neprilysin inhibition, I_f channel inhibition).
• Evaluation of emerging therapies including sodium/glucose co-transporter inhibitors, guanylate cyclase stimulators, and cardiac myosin activators.

Main Results:

• New HF drugs, such as sacubitril/valsartan and ivabradine, have emerged targeting distinct pathways.
• Treatment of comorbidities like iron deficiency improves functional capacity and reduces hospitalizations.
• Novel therapeutic targets are under investigation to further enhance HFrEF management.

Conclusions:

• Optimization of guideline-directed therapy, including new drugs and devices, is key to improving HFrEF outcomes.
• Addressing comorbidities and implementing innovative treatments can further reduce mortality and hospitalizations.
• Continued research and strategic implementation of novel therapies are essential for advancing HFrEF care.